Invicro has experience providing clinical imaging and advanced data analysis solutions in primary pulmonary disease areas, such as Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension (PAH), along with diseases with secondary respiratory involvement, such as Duchenne Muscular Dystrophy. We pride ourselves on our scientific and clinical expertise and our ability to obtain additional non-imaging (routine histology applications) data alongside the imaging data to provide pathway insights for underexplored respiratory diseases.
Invicro has a highly skilled radiochemistry team with experience in most commercially available radioisotopes used for PET/SPECT respiratory imaging as well as unique expertise in GMP implementation of novel radiotracers for first-in-human clinical studies. This includes radiolabeling of both small molecules and more challenging larger molecules, such as αvβ6 radioligand, a twenty amino acid synthetic peptide (A20FMDV2) radiolabeled with fluorine-18 ([18F]-FBA-A20FMDV2 / [18F]-IMAFIB); in-licensed from Cancer Research Technologies (CRT, UK).
We have access to subjects with a variety of lung conditions, such as COPD, PAH, IPF, fILD, lung cancer, as well as a broad range of imaging options spanning multiple modalities, including simultaneous PET-MR imaging with our GE SIGNA PETMR platform in London. Altogether, this enables us to provide relatively rapid turnaround of respiratory clinical imaging studies.
With a team of over 60 highly skilled developers and data analysts, we are able to provide both standard and bespoke image analysis solutions to meet customer requirements. Our suite of analysis tools provides both flexibility and robustness. We develop reproducible analysis workflows with appropriate audit trails to ensure both the consistency and quality of outcome measures.
- PET ([18F]FDG, [18F]IMAFIB, radiolabeled investigational medical products/new molecular entities)
- CT (with contrast: primary experience in advanced analytics for vessel segmentation)
- MRI (dynamic MRI: primary experience of advanced analytics for novel exploration of pulmonary dysfunction in DMD)
- Urinalysis, clinical chemistry, CBC (including radioactive samples), pulmonary function tests
Thought Leadership Content
Positron Emission Tomography (PET) study to evaluate biodistribution of [11C]-GSK2256098 in healthy subjects and idiopathic Pulmonary Arterial Hypertension (PAH) patients.
Quantitative analysis of dynamic [18F]-FDG PET/CT for measurement of lung inflammation.
[18F]-FBA-A20FMV2 PET Ligand dosimetry Study in Healthy Subjects.
[18F]-FBA-A20FMV2 PET characterization in the Lungs of healthy volunteers and subjects with Idiopathic Pulmonary Fibrosis (IPF) Subjects.
Assessment of post-radiotherapy fibrosis in lung using [18F]-FBA-A20FMDV2.
Semi-Automated Analysis of Diaphragmatic Motion with Dynamic Magnetic Resonance Imaging in Healthy Controls and Non-Ambulant Subjects with Duchenne Muscular Dystrophy.